Amlodipine/valsartan explained

Verifiedrevid:396294114
Type:combo
Image Class:skin-invert-image
Image Class2:skin-invert-image
Component1:Amlodipine
Class1:Calcium channel blocker
Component2:Valsartan
Class2:Angiotensin II receptor antagonist
Tradename:Exforge, Copalia, Dafiro
Dailymedid:Amlodipine and valsartan
Pregnancy Au:D
Pregnancy Au Comment:[1]
Routes Of Administration:By mouth
Atc Prefix:C09
Atc Suffix:DB01
Legal Us:Rx-only
Legal Us Comment:[2]
Legal Eu:Rx-only
Legal Eu Comment:[3] [4] [5]
Index2 Label:with HCTZ
Cas Number:1190398-97-0
Pubchem:11354874
Chemspiderid:13092186
Kegg:D09745
Kegg2:D10286

Amlodipine/valsartan, sold under the brand name Exforge among others, is a blood pressure lowering combination drug. It contains amlodipine, as the besilate, a dihydropyridine-type calcium channel blocker, and valsartan, an angiotensin II receptor antagonist.[6] This combination is usually well tolerated and effective for the reduction of blood pressure.[7]

The combination was approved for medical use in the European Union in January 2007, and in the United States in June 2007.[8]

The combination is also available with hydrochlorothiazide.[9] [10] It was approved for medical use in the United States in April 2009,[11] and in the European Union in November 2009.[12] [13] [14] The combination of amlodipine/valsartan with hydrochlorothiazide is on the World Health Organization's List of Essential Medicines.[15]

Notes and References

  1. Web site: 11 July 2019 . Amlodipine / valsartan (Exforge) Use During Pregnancy . 13 February 2020 . Drugs.com.
  2. Web site: 12 June 2019 . Exforge- amlodipine besylate and valsartan tablet, film coated . 12 February 2020 . DailyMed.
  3. Web site: 17 January 2007 . Exforge EPAR . 26 August 2024 . European Medicines Agency (EMA).
  4. Web site: 16 January 2007 . Copalia EPAR . 26 August 2024 . European Medicines Agency (EMA).
  5. Web site: 16 January 2007 . Dafiro EPAR . 26 August 2024 . European Medicines Agency (EMA).
  6. Web site: Valsartan Monograph for Professionals . 3 March 2019 . Drugs.com . American Society of Health-System Pharmacists.
  7. Eckert S, Freytag SB, Müller A, Klebs SH . September 2013 . Meta-analysis of three observational studies of amlodipine/valsartan in hypertensive patients with additional risk factors . Blood Pressure . 22 . sup1 . 11–21 . 10.3109/08037051.2013.793891 . 23713686 . 25814898.
  8. Web site: 3 October 2008 . Drug Approval Package: Exforge (amlodipine and valsartan) NDA #021990 . 19 September 2021 . U.S. Food and Drug Administration (FDA).
  9. Web site: Exforge HCT- amlodipine valsartan and hydrochlorothiazide tablet, film coated . 12 February 2020 . DailyMed.
  10. Web site: Amlodipine, Valsartan, and Hydrochlorothiazide . Drugs.com.
  11. Web site: 2 September 2009 . Drug Approval Package: Exforge HCT (Amlodipine, Valsartan, Hydrochlorothiazide) Tablets NDA #022314 . https://web.archive.org/web/20170213151805/http://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022314s000TOC.cfm . 13 February 2017 . 19 September 2021 . U.S. Food and Drug Administration (FDA).
  12. Web site: 16 October 2009 . Exforge HCT EPAR . 26 August 2024 . European Medicines Agency (EMA).
  13. Web site: 4 November 2009 . Copalia HCT EPAR . 26 August 2024 . European Medicines Agency (EMA).
  14. Web site: 4 November 2009 . Dafiro HCT EPAR . 26 August 2024 . European Medicines Agency (EMA).
  15. Book: The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list . 2025 . 10665/382243 . . Geneva . free .